Back

Respiratory syncytial virus (RSV) vaccine effectiveness and antibody correlates of protection among older adults in the Community Vaccine Effectiveness (CoVE) observational study.

2025-03-15 epidemiology Title + abstract only
View on medRxiv
Show abstract

BackgroundThe first RSV vaccines for adults 60 years and older were approved prior to the 2023-2024 respiratory virus season. This study used data from adults 60 years and older, enrolled into the Community Vaccine Effectiveness (CoVE) cohort study, in Michigan, U.S.A, to evaluate RSV vaccine effectiveness (VE) and antibody correlates of protection. MethodsA Cox proportional hazards model was used to compare incidence of symptomatic / all RSV infections in those vaccinated versus unvaccinated. ...

Predicted journal destinations